Page 403 - ILAE_Lectures_2015

51. BERTOLI S, TRENTANI C, FERRARIS C, DE GIORGIS V, VEGGIOTTI P, TAGLIABUE A. Long-term
effects of a ketogenic diet on body composition and bone mineralization in GLUT-1 deficiency syndrome: A
case series. Nutrition 2014;30(6):726-728.

52. FEKETE S, SIMKO J, GRADOSOVA I, et al. The effect of levetiracetam on rat bone mass, structure and
metabolism. Epilepsy Res. 2013;107(1–2):56-60.

53. ANWAR MJ, RADHAKRISHNA KV, VOHORA D. Phenytoin and sodium valproate but not levetiracetam
induce bone alterations in female mice. Can J Physiol Pharmacol 2014;92(6):507-511.

54. FROMMELT L, BIELOHUBY M, STOEHR BJM, MENHOFER D, BIDLINGMAIER M, KIENZLE E.
Effects of low-carbohydrate, high-fat diets on apparent digestibility of minerals and trace elements in rats.
Nutrition 2014;30(7-8):869-875.

55. TEKGUL H, SERDAROGLU G, HUSEYINOV A, GOKBEN S. Bone mineral status in pediatric outpatients
on antiepileptic drug monotherapy. J Child Neurol 2006;21(5):411-414.

56. HELLER HJ, SAKHAEE K. Anticonvulsant-induced bone disease – A plea for monitoring and treatment. Arch
Neurol 2001;58(9):1352-1353.

57. SHELLHAAS RA, BARKS AK, JOSHI SM. Prevalence and Risk Factors for Vitamin D Insufficiency Among
Children With Epilepsy. Pediatr Neurol 2010;42(6):422-426.

58. MENON B, HARINARAYAN CV, RAJ MN, VEMURI S, HIMABINDU G, AFSANA TK. Prevalence of low
dietary calcium intake in patients with epilepsy: a study from South India. Neurol India 2010;58(2):209-212.

59. DREZNER MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav. 2004;5 Suppl 2:S41-
S47.

60. KUBOTA F, KIFUNE A, SHIBATA N, et al. Bone mineral density of epileptic patients on long-term
antiepileptic drug therapy: a quantitative digital radiography study. Epilepsy Res 1999;33(2-3):93-97.

61. PEDRERA JD, CANAL ML, CARVAJAL J, et al. Influence of vitamin D administration on bone ultrasound
measurements in patients on anticonvulsant therapy. Eur J Clin Invest 2000;30(10):895-899.

62. RIEGER-WETTENGL G, TUTLEWSKI BR, STABREY A, et al. Analysis of the musculoskeletal system in
children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics
2001;108(6):art-e107.

63. STEPHEN LJ, MCLELLAN AR, HARRISON JH, et al. Bone density and antiepileptic drugs: a case-controlled
study. Seizure – Eur J Epilepsy 1999;8(6):339-342.

64. BEERHORST K, SCHOUWENAARS FM, TAN IY, ALDENKAMP AP. Epilepsy: fractures and the role of
cumulative antiepileptic drug load. Acta Neurol Scand 2012;125(1):54-59.

65. SHETH RD, WESOLOWSKI CA, JACOB JC, et al. Effect of carbamazepine and valproate on bone-mineral
density. J Pediatr 1995;127(2):256-262.

66. AKIN R, OKUTAN V, SARICI U, ALTUNBAS A, GOKCAY E. Evaluation of bone mineral density in
children receiving antiepileptic drugs. Pediatr Neurol 1998;19(2):129-131.

67. KAFALI G, ERSELCAN T, TANZER F. Effect of antiepileptic drugs on bone mineral density in children
between ages 6 and 12 years. Clin Pediatr 1999;38(2):93-98.

68. ECEVIT CG, AYDOGAN A, KAVAKLI T, ALTINOZ S. Effect of carbamazepine and valproate on bone
mineral density. Pediatr Neurol 2004;31(4):279-282.

69. SHETH RD, HERMANN BP. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol
2007;37(4):250-254.

70. DIMIC MD, DIMIC NA. Bone mineral density in epileptic adolescents treated with antiepileptic monotherapy.
Eur J Neurol 2014;21:500-500.

71. BABAYIGIT A, DIRIK E, BOBER E, CAKMAKCI H. Adverse effects of antiepileptic drugs on bone mineral
density. Pediatr Neurol 2006;35(3):177-181.

72. SHETH RD, BINKLEY N, HERMANN BP. Progressive bone deficit in epilepsy. Neurology 2008;70(3):170-
176.

73. SHETH RD, BINKLEY N, HERMANN BP. Gender differences in bone mineral density in epilepsy. Epilepsia
2008;49(1):125-131.

74. TSUKAHARA H, KIMURA K, TODOROKI Y, et al. Bone mineral status in ambulatory pediatric patients on
long- term anti-epileptic drug therapy. Pediatr Int 2002;44(3):247-253.

75. DESAI TK, CARLSON RW, GEHEB MA. Prevalence and clinical implications of hypocalcaemia in acutely
ill patients in a medical intensive care setting R. Am J Med 1988;84(2):209-214.

76. CUMMINGS SR, NEVITT MC, BROWNER WS, et al. Risk factors for hip fracture in white women. N Engl
J Med 1995;332(12):767-773.

77. ENSRUD KE, WALCZAK TS, BLACKWELL T, ENSRUD ER, BOWMAN PJ, STONE KL. Antiepileptic
drug use increases rates of bone loss in older women – A prospective study. Neurology 2004;62(11):2051-2057.

78. ENSRUD KE, WALCZAK TS, BLACKWELL TL, ENSRUD ER, BARRETT-CONNOR E, ORWOLL ES.
Antiepileptic drug use and rates of hip bone loss in older men - A prospective study. Neurology
2008;71(10):723-730.

79. NICE. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and
secondary care: Pharmacological update. London 1/25/2012 2012. Clinical Guideline 20.

80. HIPPISLEY-COX J, COUPLAND C. Derivation and validation of updated QFracture algorithm to predict risk
of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ
2012;344(e3427):1-16.

81. PACK A. Bone health in people with epilepsy: Is it impaired and what are the risk factors. Seizure
2008;17(2):181-186.

82. BRIGO F, STORTI M, LOCHNER P, et al. Tongue biting in epileptic seizures and psychogenic events: An
evidence-based perspective. Epilepsy Behav 2012;25(2):251-255.